Research programme : anti-fibrotic therapeutics - ProMetic Life Sciences

Drug Profile

Research programme : anti-fibrotic therapeutics - ProMetic Life Sciences

Alternative Names: PBI-4425; PBI-4547

Latest Information Update: 22 Jul 2016

Price : $50

At a glance

  • Originator ProMetic Life Sciences
  • Class Small molecules
  • Mechanism of Action Cell differentiation modulators; Colony stimulating factor stimulants; Cytokine modulators; Erythropoiesis stimulants; Extracellular matrix protein inhibitors; Immunomodulators; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic neuropathies; Hepatic fibrosis; Idiopathic pulmonary fibrosis

Most Recent Events

  • 13 Apr 2016 Preclinical trials in Hepatic fibrosis in Canada (PO)
  • 09 Nov 2015 Preclinical trial in Idiopathic pulmonary fibrosis in Canada (unspecified route)
  • 09 Nov 2015 Preclinical trial in Diabetic neuropathies in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top